Risner, M. E. et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254

World Wide Development, Research and Development, GlaxoSmithKline, Research Triangle Park, NC 27709-3398, USA.
The Pharmacogenomics Journal (Impact Factor: 5.51). 01/2006; 6(4):246-54. DOI: 10.1038/sj.tpj.6500369
Source: PubMed

ABSTRACT Mild-to-moderate AD patients were randomized to placebo or rosiglitazone (RSG) 2, 4 or 8 mg. Primary end points at Week 24 were mean change from baseline in AD Assessment Scale-Cognitive (ADAS-Cog) and Clinician's Interview-Based Impression of Change Plus Caregiver Input global scores in the intention-to-treat population (N=511), and results were also stratified by apolipoprotein E (APOE) genotype (n=323). No statistically significant differences on primary end points were detected between placebo and any RSG dose. There was a significant interaction between APOE epsilon4 allele status and ADAS-Cog (P=0.014). Exploratory analyses demonstrated significant improvement in ADAS-Cog in APOE epsilon4-negative patients on 8 mg RSG (P=0.024; not corrected for multiplicity). APOE epsilon4-positive patients did not show improvement and showed a decline at the lowest RSG dose (P=0.012; not corrected for multiplicity). Exploratory analyses suggested that APOE epsilon4 non-carriers exhibited cognitive and functional improvement in response to RSG, whereas APOE epsilon4 allele carriers showed no improvement and some decline was noted. These preliminary findings require confirmation in appropriate clinical studies.

Download full-text


Available from: Allen D Roses, May 10, 2014
1 Follower
  • Source
    • "Through the advances in pharmacological therapy, many oral antidiabetic agents have become available. Interestingly, oral antidiabetic drugs such as thiazolidinedione and metformin have been shown to have beneficial effects to slow the progression of dementia in both clinical and animal studies [17] [18]. However, many of these pharmaceutical agents are associated with various undesirable side-effects, such as weight gain, fluid retention, and increased risk for heart failure, limiting their compliance and utility in clinical practice. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diabetes mellitus (DM) is a metabolic disorder affecting a large number of people worldwide. Numerous studies have demonstrated that DM can cause damage to multiple systems, leading to complications such as heart disease, cancer, and cerebrovascular disorders. Numerous epidemiological studies have shown that DM is closely associated with dementia and cognition dysfunction, with recent research focusing on the role of DM-mediated cerebrovascular damage in dementia. Despite the therapeutic benefits of antidiabetic agents for the treatment of DM-mediated cognitive dysfunction, most of these pharmaceutical agents are associated with various undesirable side-effects and their long-term benefits are therefore in doubt. Early evidence exists to support the use of traditional Chinese medicine (TCM) interventions, which tend to have minimal toxicity and side-effects. More importantly, these TCM interventions appear to offer significant effects in reducing DM-related complications beyond blood glucose control. However, more research is needed to further validate these claims and to explore their relevant mechanisms of action. The aims of this paper are (1) to provide an updated overview on the association between DM and cognitive dysfunction and (2) to review the scientific evidence underpinning the use of TCM interventions for the treatment and prevention of DM-induced cognitive dysfunction and dementia.
    International Journal of Endocrinology 01/2015; 2015. DOI:10.1155/2015/810439 · 1.52 Impact Factor
  • Source
    • "PPAR␥ activation has been shown to increase neuron survival and decrease lesion sizes in animal models of Parkinson's disease, central inflammation, intracerebral hemorrhage, and cerebral ischemia (Heneka et al., 2000; Breidert et al., 2002; Dehmer et al., 2004; Ou et al., 2006; Victor et al., 2006; Zhao et al., 2006). PPAR␥ agonists have been shown to improve impaired hippocampus-dependent cognitive function in neurodegenerative disorders in both human and animals (Watson et al., 2005; Pedersen et al., 2006; Risner et al., 2006; Escribano et al., 2009; Rodriguez- Rivera et al., 2011; Denner et al., 2012). Our finding of IUGR-induced reductions in hippocampal PPAR␥ expression suggests that PPAR␥ contribute to impaired hippocampal development and impaired learning and memory function seen in IUGR rats. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Intrauterine growth restriction (IUGR) programs neurodevelopmental impairment and long-term neurological morbidities. Neurological morbidities in IUGR infants are correlated with changes hippocampal volume. We previously demonstrated that IUGR alters hippocampal cellular composition in both neonatal and juvenile rat pups in association with altered hippocampal gene expression and epigenetic determinants. PPARγ signaling is important for neurodevelopment as well as epigenetic integrity in the brain via the PPARγ-Setd8-H4K20me1 axis and Wnt signaling. We hypothesized that IUGR would decrease expression of PPARγ, Setd8, and H4K20me1 in juvenile rat hippocampus. We further hypothesized that reduced PPARγ-Setd8-H4K20me1 would be associated with reduced Wnt signaling genes Wnt3a and β-catenin, and wnt target gene Axin2. To test our hypothesis we used a rat model of uteroplacental insufficiency-induced IUGR. We demonstrated that PPARγ localizes to oligodendrocytes, neurons and astrocytes within the juvenile rat hippocampus. We also demonstrated that IUGR reduces levels of PPARγ, Setd8 and H4K20me1 in male and female juvenile rat hippocampus in conjunction with reduced Wnt signaling components in only male rats. We speculate that reduced PPARγ and Wnt signaling may contribute to altered hippocampal cellular composition which, in turn, may contribute to impaired neurodevelopment and subsequent neurocognitive impairment in IUGR offspring.
    International Journal of Developmental Neuroscience 11/2014; 38. DOI:10.1016/j.ijdevneu.2014.07.008 · 2.92 Impact Factor
  • Source
    • "For example, the APOE3/E4 status has also been shown to influence the results of clinical trials with medium chain triglycerides [24], intravenous immunoglobulins [25], and bapineuzumab [26]. Interactions between treatment and APOE status were also initially reported with glitazone, statins and cholinesterase inhibitors but not confirmed in larger studies [27] [28] [29] [30] [31]. One limitation of AD studies thus far has been the lack of studies specifically targeted to APOE variants or possibly other genotypes as a selection criteria for the patient group. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A brief overview of the evidence for omega-3 fatty acids and, in particular, of docosahexaenoic acid (DHA), involvement in cognition and in dementia is given. Two studies are presented in this regard in which the key intervention is a DHA supplement. The fist, the MIDAS Study demonstrated that DHA can be of benefit for episodic memory in healthy adults with a mild memory complaint. The second, the ADCS AD trial found no benefit of DHA in the primary outcomes but found an intriguing benefit for cognitive score in ApoE4 negative allele patients. This leads to a consideration of the mechanisms of action and role of ApoE and its modulation by DHA. Given the fundamental role of ApoE in cellular lipid transport and metabolism in the brain and periphery, it is no surprise that ApoE affects n-3 PUFA brain function as well. It remains to be seen to what extent ApoE4 deleterious effect in AD is associated with n-3 PUFA-related cellular mechanisms in the brain and, more specifically, whether ApoE4 directly impairs the transport of DHA into the brain, as has been suggested.
    Prostaglandins Leukotrienes and Essential Fatty Acids 10/2014; 92. DOI:10.1016/j.plefa.2014.10.003 · 1.98 Impact Factor
Show more